Background {#Sec1}
==========

Tuberculosis (TB), an infectious disease caused by the bacillus *Mycobacterium tuberculosis* (MTB), is spread from person to person predominantly through an airborne route. It remains a major global health problem as it causes ill-health among millions of people. After the human immunodeficiency virus (HIV), TB ranks as the second leading cause of death from an infectious disease worldwide \[[@CR1], [@CR2]\]. The lack of a simple and effective diagnostic test that can be utilised in resource-limited settings, where the infection is endemic, has hindered its control \[[@CR3]\]. According to the World Health Organization in 2015, there were 10.4 million new cases of TB worldwide that resulted in 1.8 million deaths and over 95% were from low- and middle-income countries \[[@CR4], [@CR5]\]. In the UK, a total of 5758 TB cases were notified the by Public Health England in 2015 \[[@CR6]\].

Over the past decade, the TB diagnostics pipeline has expanded, with several technologies showing promise \[[@CR7]\]. New diagnostic tests are continually being developed, driven by demands for improvements in speed, cost, ease of use, patient safety and diagnostic accuracy \[[@CR8]\]. Consequently, there are often several tests available for the diagnosis of a condition. Polymerase chain reaction (PCR) technology was introduced in the mid-1990s and has revolutionised the diagnosis of infectious diseases. Nucleic acid amplification assays (NAAAs) are commonly used in routine laboratories in industrialised countries for rapid and specific detection of MTB complex in clinical specimens. Over time, a significant improvement of PCR technologies has been achieved with the development of real-time polymerase chain reaction (RT-PCR) assay testing platforms. RT-PCR assay is commonly used to determine whether [DNA](http://en.wikipedia.org/wiki/DNA) or a sequence of the MTB is present in a sample and detects amplified DNA as the reaction progresses in real time. It monitors the amplification of a targeted [DNA](https://en.wikipedia.org/wiki/DNA)/RNA molecule during the PCR amplification by using complementary primers, i.e. in real-time, and not at its end, as in conventional PCR. A RT-PCR assay uses marked probes with fluorophores that emit fluorescence alongside amplification. The cycle of the PCR protocol in which there appears significant fluorescence is proportional to the quantity of DNA/RNA present in the sample. This value is called cycle threshold (*C* ~t~) or cycle quantification (*C* ~q~). RT-PCR is sensitive, specific and reproducible, and automation of the procedure reduces hands-on time and decreases the risk of cross-contamination \[[@CR9]\].

RT-PCR-based methods have been shown to detect MTB with higher sensitivity and specificity directly from positive cultures or clinical specimens within 2 h \[[@CR10]\]. It requires approximately 6 copies/ml of MTB DNA in comparison to smear microscopy that requires 5000--10,000 bacilli/ml. For concentrated samples, such as sputum, sensitivity of smear microscopy has been reported to increase up to 39%. Culture which is the reference standard, requires at least 100 viable bacilli to obtain a positive culture with a turn-a-round time of between 2 and 10 weeks \[[@CR11]\]. Therefore, to adequately treat and effectively control MTB, there is a need for effective, rapid and accurate diagnosis.

This review assesses all the available published primary research studies to provide summary estimates of the effectiveness of RT-PCR assay for the detection of MTB from pulmonary and extra-pulmonary samples. It summarises current evidence-based clinical practice that can help to develop future guidelines and healthcare policy when choosing the most appropriate tool for rapid and accurate detection of MTB in pathological samples on routine basis.

Methods {#Sec2}
=======

This review is in accord with the standardised written protocol (systematic review registration: PROSPERO CRD42015027534) that followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement guidelines \[[@CR12]\]. Additional file [1](#MOESM1){ref-type="media"} shows the PRISMA checklist. Quality of included studies was assessed by Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) \[[@CR13]\]. Institutional ethical review approval was not needed for this review.

Strategy {#Sec3}
--------

### Electronic searches {#Sec4}

Search terms (included 'tuberculosis', '*Mycobacterium tuberculosis*', 'pulmonary tuberculosis', 'extra-pulmonary tuberculosis', 'real-time polymerase chain reaction', 'RT-PCR', 'nucleic acid amplification test', 'culture-based media', 'liquid media' and 'solid media') (see Additional file [2](#MOESM2){ref-type="media"} for search terms) were used to generate a list of primary studies in any language from January 1995 to November 2016 (RT-PCR became a tool for detecting and quantifying expression profiles of selected genes in the mid-1990s. A search using the key words real-time and PCR yielded seven publications in 1995). Two investigators (EB, BC) independently and systematically carried out the search. Searches using electronic bibliographic databases (MEDLINE via PubMed, EMBASE, BIOSIS Citation Index, Web of Science, SCOPUS, ISI Web of Knowledge, Cochrane Infectious Diseases Group Specialised Register (CIDG SR), Cochrane Registry of Diagnostic Studies, National Institute for Health Research, PROSPERO, Google Scholar Turning Research into Practice (TRIP) and [International Union Against Tuberculosis and Lung Disease](https://www.theunion.org/) (IUALTD)) took place in July 2015 and was updated in November 2016. The MEDLINE search strategy is outlined in Additional file [2](#MOESM2){ref-type="media"}. The MEDLINE search was imported to EMBASE, Cochrane Infectious Diseases Group Specialised Register and other databases to identify additional records \[[@CR14], [@CR15]\]. These attempts to avoid missing studies achieve a more reliable estimate of diagnostic accuracy which is important to ensure that the process of identifying studies is as thorough and unbiased as possible.

We reviewed reference lists of included articles and any relevant review articles identified through the above methods. Conference Proceedings Citation Index-Science (CPCI-S) was searched. We searched the portal of the World Health Organization (WHO) International Clinical Trials Registry Platform (<http://www.who.int/trialsearch>), to identify ongoing trials and StopTB Partnership's New Diagnostics Working Group ([www.stoptb.org/wg/new_diagnostics/](http://www.stoptb.org/wg/new_diagnostics/)). Personal communication was sent to the corresponding author of 'Detection of Mycobacterial DNA directly from FNAC samples of tuberculous lymphadenopathy using real-time PCR: a preliminary study' to ask for study data. Forward citation searching of relevant articles using the PubMed related articles and relevant guidelines (i.e. [National Institute for Health and Care Excellence](https://www.nice.org.uk/) (NICE) in the UK) was performed. Focus was placed on TB meetings for example annual scientific conferences of TB diagnosis and control such as the IUALTD. Besides full articles, abstracts and letters to the editor with sample sizes \>20 were also considered for inclusion. There was no language limitation to the search. Abstracts or articles in languages other than English were screened using 'Google Translator'.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Study designs such as cross-sectional studies, cohort studies (prospective and retrospective) and case-control designs for the detection of MTB from human pathological samples of any patient age were eligible for inclusion if the studies (1) described original research, (2) compared RT-PCR assay to a reference/gold standard method--- culture-based (either liquid or solid) assay, (3) reported total number of patients tested and positive/negative results that allowed calculation of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN) and (4) were published between 1995 and 2016 in any language. Studies were excluded if (1) all samples were not tested by reference/gold standard test---culture-based (either liquid or solid) assay, (2) application of RT-PCR assay for determining drug resistance, (3) RT-PCR assay was not used in the study, (4) reference test was a combination of greater than one diagnostic test, (5) it included animal studies, (6) RT-PCR assay was used for detecting non-tuberculosis mycobacteria, (7) RT-PCR assay was used for detecting MTB from clinical isolates and not the pathological specimens/samples and (8) possible duplicate publication, when an author published more than one study. The existence of overlapping study populations was ascertained by checking sample recruitment sites and/or periods. The article reporting on the largest number of samples was included in our study.

Selection of studies {#Sec6}
--------------------

Full-text articles were screened independently (by EB and BC, using a PRISMA flow chart \[[@CR12]\]) for eligibility for use in the study to minimise bias in selection. Any disagreements were resolved through discussion and where needed, by a third reviewer. Any rejected studies were documented.

Data extraction {#Sec7}
---------------

Data were extracted (independently by EB and BC) from each selected study using a predetermined list of categories/characteristics: participants/population, index test, reference test, country, disease and target sequence for detection of MTB DNA (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of the included studiesAuthor year \[n\]CountryTotal number of samples (*N*)Reference test: cultureIndex test RT-PCRTarget sequencePTBEPTBAlbuquerque, 2014 \[[@CR24]\]Brazil140--LJ 7H9TaqManIS6110 geneAntonenka, 2013 \[[@CR25]\]Germany116--MGIT LJTaqManrpoB as target sequenceArmand, 2011 \[[@CR26]\]France7047LJ BacT/Alert MPTaqManIS6110 geneBarletta, 2014 \[[@CR27]\]Belgium112--LJLight Cycler 480 Real-time PCR assayIS6110 geneBloemberg, 2013 \[[@CR28]\]Switzerland8292807H11 MGITCOBAS TaqMan16S rRNA geneCausse, 2011 \[[@CR23]\]Spain--340LJ 7H9COBAS TaqMan MTB16S rRNA geneChadran, 2010 \[[@CR29]\]India72--LJ MGIT 960COBAS TaqManIS6110 geneChaidir, 2012 \[[@CR30]\]Indonesia--207Ogawa egg medium MB/BacTalertIS6110-PCR BioRadIS6110 geneChang, 2015 \[[@CR31]\]South Korea2859--MGIT 960 3% OgawaAdvanSure TB/NTM Real-time PCR assayIS6110 geneChen, 2012 \[[@CR32]\]China178--BACTEC™ MGIT™ 960Real-time PCR assay used the ABI Prism SDS 7000IS6110 geneChitnis, 2010 \[[@CR33]\]India--204LJ MGIT-BACTECGeno-Sen's MTB complex Real-time PCR assay16S rRNA geneCho, 2015 \[[@CR34]\]South Korea23846262% Ogawa medium MGIT 960COBAS TaqMan MTB assayIS6110 geneChoe, 2011 \[[@CR35]\]South Korea--1293% OgawaTaqManReal-time MTB PCR, targeting the senX3-regX3 intergenic regionChoi, 2013 \[[@CR36]\]South Korea36065MGIT 960COBAS TaqMan MTB assayIS6110 geneDayal, 2010 \[[@CR37]\]India--47BacT/AlertReal-time PCR targeting 16SrRNA using Light Cycler RNA amplification syber green 1 kit (Roche Applied Biosciences, Germany)16S rRNA geneEl Khechine, 2009 \[[@CR38]\]France--134BACTEC 9000 MB LJNot specifiedIS6110 geneFeizabadi, 2012 \[[@CR39]\]Iran247--LJTaqManCytochrome P450 Cyp 141 geneFriedrich, 2011 \[40\]South Africa--25MGIT 960Xpert*rpo*B probeGous, 2012 \[[@CR41]\]South Africa--39BACTEC 9000 MB LJLight Cycler mycobacterium detection assay (LCTB)Hillemann, 2011 \[42\]Germany--521MGIT 960 LJGenoType MTBC and CM/AS assays (Hain Lifescience)*rpo*B probeHofmann-Thiel, 2016 \[[@CR43]\]Germany608107MGIT LJAbbott Real-time MTBAntigen b (*PAB*) and the multicopy insertion element IS6110 geneHuh, 2015 \[[@CR44]\]South Korea6852--MGIT 960 LJCOBAS TaqMan16S rRNA geneIn, 2014 \[[@CR45]\]South Korea247--BACTEC MGIT 960 LJUltrafast NBS LabChip G2--3 (NanoBioSys)Jönsson, 2015 \[46\]Sweden23881005MGIT 960 LJCOBAS TaqMan16S rRNA geneKheawon, 2012 \[[@CR47]\]Thailand430--LJ mediumCommercial PCR Kits AmplicorIS6110 gene and MPB64 geneKim, 2011 \[[@CR48]\]South Korea96310Solid cultureUltrafast NBS LabChip G2--3 system (NanoBioSys)61 genomic DNA (gDNA) samples of MTBLee, 2011 \[[@CR49]\]South Korea99--3% OgawaAdvanSure TB/NTM Real-time PCR assayIS6110 geneLee, 2010 \[[@CR50]\]South Korea--1433% OgawaLight Cycler 2.0senX3-regX3 intergenic regionLee, 2013 \[[@CR51]\]Taiwan587--BACTEC MGIT 960 LJCOBAS TaqMan MTB assayIS6110 geneLim, 2014 \[[@CR52]\]South Korea1167COBAS TaqMan MTB assayLinasmita, 2012 \[[@CR53]\]Thailand--73MGIT 960COBAS TaqMan MTB assay16S ribosomal RNA gene of *M. tuberculosis*Lira, 2013 \[[@CR54]\]Brazil165--LJABI Prism 7500 Sequence Detection System (Applied Biosystems) using TaqMan-specific probeIS6110 geneLuo, 2010 \[[@CR55]\]USA--70Culture-based assay (type not stated)SmartCycler II instrumentIS6110 geneMalhotra, 2012 \[56\]India--5557H9COBAS TaqmanIS6110 geneMangat, 2016 \[[@CR57]\]India74--MGIT 960 LJRoche Light Cycler 480 Real-time PCR system123 bp fragment of insertion element IS6110 sequenceMiller, 2011 \[[@CR58]\]North Carolina, USA89237H9 LJXpertLaboratory-developed test targeting IS6110 geneMoure, 2012 \[[@CR59]\]Spain--149MGIT 960 LJGX assayPark, 2013 \[[@CR60]\]South Korea320--MGIT 960 3% OgawaCOBAS TaqManIS6110 genePinhata, 2015 \[61\]Brazil715--MGIT 960 Ogawa--Kudoh slantRoche Light Cycler 480 II systemmpt64 geneRachow, 2011 \[[@CR11]\]Tanzania292--Both liquid and solid (type not stated)Cepheid Xpert MTB/RIF assayrpoB as target geneRosso, 2011 \[[@CR62]\]Brazil--158LJABI Prism 7500 system (Applied Biosystems)IS6110 geneSethi, 2012 \[[@CR63]\]India5022MGIT 960 LJIn-house mpt64 Real-time PCRmpt64 geneSharma, 2015 \[[@CR64]\]India1480--MGIT 960 LJABI prism 3130xl genetic analyser (Applied Biosystems)81-bp rpoB geneTortoli, 2012 \[[@CR65]\]Italy43401727MGIT 960 LJCepheid Xpert MTB/RIF assayrpoB as target geneWang, 2013 \[[@CR66]\]China30--Bact/Alert 3DLight Cycler 480 (Roche)Yang, 2011 \[[@CR67]\]Taiwan1093--MGIT 960 LJ 7H11COBAS TaqMan MTB assayIS6110 geneKey: *LJ* Löwenstein-Jensen, *Middlebrook 7H9 Broth* Liquid growth medium, *Middlebrook 7H11* Solid medium, *MGIT* Mycobacterium Growth Indicator Tube, *PTB* Pulmonary TB, *EPTB* Extra-pulmonary TB, *\[n\]* reference list number

Assessment of study quality {#Sec8}
---------------------------

The methodological quality for the included studies was assessed independently (EB and BC) according to the four domains (patient selection, index test, reference standard and flow and timing) of the QUADAS-2 tool \[[@CR13]\]. The study QUADAS-2 quality criteria are given in Additional file [3](#MOESM3){ref-type="media"}.

Data synthesis and meta-analysis {#Sec9}
--------------------------------

For each study, we computed measures of test accuracy using standard methods recommended for meta-analysis of diagnostic studies: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and 95% confidence intervals (CI) \[[@CR16]--[@CR18]\] see Additional file [4](#MOESM4){ref-type="media"}. TP, FP, TN and FN were extracted directly from source papers. Where this information was not available, values were calculated from the data provided in the article. To assess the overall accuracy, a DOR was calculated using the DerSimonian-Laird random-effect model, which accounts for both within-study variability (random error) and between-study variability (heterogeneity) along with the area under the summary receiver operating characteristic (SROC) curve using the bivariate model \[[@CR17], [@CR18]\]. The bivariate model considers potential threshold effects and the correlation between binary tests (sensitivity and specificity). These measures were pooled using the random-effects model \[[@CR17], [@CR18]\]. Each study in the meta-analysis contributed a pair of numbers: sensitivity and specificity. Since these measures are correlated, we summarised their joint distribution using a SROC curve. The SROC curve presents a global summary of test performance and shows the trade-off between sensitivity and specificity. A symmetric curve suggests that the variability in accuracy between studies is explained, in part, by differences in thresholds used by the studies. The area under the SROC curve is a global measure of overall performance of the test. An area under the curve value of 1 indicates perfect discriminatory ability of the test, while an area under the curve value of 0.5 means that the test does not have discriminating ability \[[@CR17], [@CR18]\].

Data were analysed using Meta-DiSC (version 1.4), Reviewing Manager ver. 5.3 (Cochrane Collaboration, Oxford, UK) \[[@CR18], [@CR19]\]. The data were displayed graphically on forest plots and SROC plots. The SROC curve was fitted using the Littenberg-Moses method \[[@CR20]\].

Publication bias was not evaluated as this is not usually recommended in the meta-analysis for diagnostic test accuracy \[[@CR21]\]. Generally, a diagnostic accuracy study does not test a hypothesis; therefore, there is no *p* value for authors and publishers that may influence decisions about publication which are based on the statistical significance of the results \[[@CR22]\].

Investigations of heterogeneity {#Sec10}
-------------------------------

Exploring heterogeneity is a critical issue (1) to understand the possible factors that influence accuracy estimates and (2) to evaluate the appropriateness of statistical pooling of accuracy estimates using random-effects meta-analysis to generate sensitivity and specificity with 95% CIs from various studies \[[@CR22]\].

The heterogeneities among studies were assessed visually with forest plots and SROC curves with 95% prediction regions and statistically with chi-squared (*χ* ^2^) and using I-squared (*I* ^2^) statistics with the following interpretation: *I* ^2^ = 0, no heterogeneity; 0 \< *I* ^2^ \< 25, mild heterogeneity; 25 ≤ *I* ^2^ \< 50, moderate heterogeneity; 50 ≤ *I* ^2^ \< 75, strong heterogeneity; 75 ≤ *I* ^2^ \< 90, considerable heterogeneity and 90 ≤ *I* ^2^, extreme heterogeneity \[[@CR23]\]. Source of heterogeneity was investigated using stratified (subgroup) analyses. The following factors were specified a priori as potential sources of heterogeneity (1) studies of RT-PCR assay type: CobasTaqMan as the RT-PCR assay, Light Cycler as the RT-PCR assay, Cepheid & others and (2) RT-PCR assay target sequence gene: IS6110 as the RT-PCR assay target sequence gene, 16SRNA as the RT-PCR assay target sequence gene and other genes as the RT-PCR assay (see Tables [1](#Tab1){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).

Results {#Sec11}
=======

Study characteristics {#Sec12}
---------------------

Of the 6706 references that were identified initially, 1628 potentially relevant citations were selected based on relevance to the study topic. An additional 27 studies were identified from grey literature and references of full-text articles. After screening all the titles and abstracts, removing the duplicates and excluding the ineligible studies, 46 articles \[[@CR10], [@CR23]--[@CR67]\] were selected for full-text review and meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). Twenty-one \[[@CR10], [@CR24], [@CR25], [@CR27], [@CR29], [@CR31], [@CR32], [@CR39], [@CR44], [@CR45], [@CR47], [@CR49], [@CR51], [@CR52], [@CR54], [@CR57], [@CR60], [@CR61], [@CR64], [@CR66], [@CR67]\] reported detection of pulmonary TB (PTB), fifteen \[[@CR23], [@CR30], [@CR33], [@CR35], [@CR37], [@CR38], [@CR40]--[@CR42], [@CR50], [@CR53], [@CR55], [@CR56], [@CR59], [@CR62]\] reported detection of extra-pulmonary TB (EPTB) and ten \[[@CR26], [@CR28], [@CR34], [@CR36], [@CR43], [@CR46], [@CR48], [@CR58], [@CR63], [@CR65]\] reported on both types of pathological sample. Table [1](#Tab1){ref-type="table"} summarises the main characteristics of the included studies. In total, the review and meta-analysis included 35,380 (28,406 PTB and 6974 EPTB) pathological samples obtained from 21 countries with high, moderate and low prevalence of TB. Studies included patients with infections identified in primary, secondary and tertiary healthcare settings. Details of the RT-PCR assays used are summarised in Table [1](#Tab1){ref-type="table"}.Fig. 1The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

The methodological quality of studies (assessed by the QUADAS-2 tool) was generally high, with 37 of the studies meeting all four domains of the criteria (see Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). All studies used RT-PCR assay as index test and culture-based assay as the reference test.Fig. 2Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies Fig. 3Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study

Meta-analysis {#Sec13}
-------------

Results as 95% CI values were as follows: overall sensitivity 0.82 (95% CI 0.81--0.83) and 0.70 (95% CI 0.67--0.72) and the values and confidence intervals for specificity are similar 0.99 (95% CI 0.99--0.99) for PTB and EPTB samples, respectively. AUC was 0.99 and 0.96 for PTB and EPTB samples, respectively. The summary estimates of PTB for heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 586.21, 361.23, 285.01, 359.13 and 242.84, respectively, and *p* = 0 indicating significant heterogeneity across studies. *I* ^2^ was between 87.60 and 92.80% showing significant heterogeneity. The summary estimates of EPTB heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 272.48, 105.48, 75.37, 186.30 and 70.73, respectively, and *p* = 0 indicating significant heterogeneity across studies. *I* ^2^ was between 66.10 and 91.20% showing significant heterogeneity. There were considerable heterogeneities (see Table [2](#Tab2){ref-type="table"}, Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}) in these data.Table 2Summary of statistical results for pulmonary tuberculosis (PTB) and extra-pulmonary tuberculosis (EPTB) pathological samplesTest propertySummary measure of test accuracy^a^ (95% CI)Test for heterogeneity(*χ* ^2^) (df = 24)(*I* ^2^)*p* valuePTB (*n* = 31; ^b^28,406) AUC = 0.99 Sensitivity0.82 (0.81--0.83)586.2192.8%\< 0.001 Specificity0.99 (0.99--0.99)361.2391.7%\< 0.001 Positive likelihood ratio (PLR)42.77 (28.23--64.81)285.0189.5%\< 0.001 Negative likelihood ratio (NLR)0.16 (0.12--0.20)359.1391.6%\< 0.001 Diagnostic odds ratio (DOR)324.26 (189.08--556.09)242.8487.6%\< 0.001EPTB (*n* = 25; ^b^6974) AUC = 0.96 Sensitivity0.70 (0.67--0.72)272.4891.20%\< 0.001 Specificity0.99 (0.99--0.99)105.4877.20%\< 0.001 Positive likelihood ratio (PLR)29.82 (17.86--49.78)75.3768.20%\< 0.001 Negative likelihood ratio (NLR)0.33 (0.26--0.42)186.3087.10%\< 0.001 Diagnostic odds ratio (DOR)125.20 (65.76--238.36)70.7366.10%\< 0.001*χ* ^2^ chi-squared, *df* degree of freedom, *I* ^2^ I-squared, *n* number of studies, *CI* confidence interval, *AUC* area under receiver operating characteristics curve, *PTB* pulmonary tuberculosis, *EPTB* extra-pulmonary tuberculosis^a^Random-effects model^b^Number of specimens Fig. 4Forest plot of estimates of RT-PCR assay for pulmonary tuberculosis (PTB). TP = true positive, FP = false positive, FN = false negative, TN = true negative. Between brackets are the 95% CI of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue squares) and its 95% CI (black horizontal line) Fig. 5Forest plot of estimates of RT-PCR assay for extra-pulmonary tuberculosis (EPTB). TP = true positive, FP = false positive, FN = false negative, TN = true negative. Between brackets are the 95% CI of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue squares) and its 95% CI (black horizontal line)

Subgroup analyses by RT-PCR assay type {#Sec14}
--------------------------------------

I.With CobasTaqMan (Table [1](#Tab1){ref-type="table"}) as the RT-PCR assay (17 studies, 19,814 specimens), the results were as follows: sensitivity 0.78 (95% CI 0.76--0.80), specificity 10.99 (95% CI, 0.99--0.99) and AUC 0.98. A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper left corner, the higher the overall accuracy of the test. The summary estimates of CobasTaqMan heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 205.13, 127.21, 98.14, 134.36 and 47.6, respectively, and *p =* \< 0.001 indicating significant heterogeneity across studies. *I* ^2^ was between 70.50 and 91.20% showing significant heterogeneity. The results for subgroup analysis by RT-PCR assay type are as presented in Table [3](#Tab3){ref-type="table"} and Additional file [5](#MOESM5){ref-type="media"} and show considerable heterogeneity.II.With Light Cycler (Table [1](#Tab1){ref-type="table"}) as the RT-PCR assay (7 studies, 1159 specimens), the results were as follows: sensitivity 0.85 (95% CI 0.80--0.88), specificity 0.99 (95% CI 0.98--0.99) and AUC 0.97. A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper left corner, the higher the overall accuracy of the test. The summary estimates of Light Cycler heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 61.71, 10.09, 17.45, 63.77, 20.35 respectively and *p =* \< 0.121 indicating significant heterogeneity across studies. *I* ^2^ was between 66.40 and 90.30% showing significant heterogeneity. The results for subgroup analysis by RT-PCR assay type are as presented Table [3](#Tab3){ref-type="table"} and Additional file [5](#MOESM5){ref-type="media"} and show considerable heterogeneity.III.With Cepheid and others (Table [1](#Tab1){ref-type="table"}) as the RT-PCR assay (22 studies, 14,839 specimens), the results were as follows: sensitivity 0.78 (95% CI 0.77--0.80), specificity 0.99 (95% CI 0.99--0.99) and AUC 0.99. A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper left corner, the higher the overall accuracy of the test. The summary estimates of Cepheid and others heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 729.43, 299.13, 234.62, 594.30 and 208.25, respectively, and *p* = 0 indicating significant heterogeneity across studies. *I* ^2^ was between 89.90 and 97.10% showing significant heterogeneity. The results for subgroup analysis by RT-PCR assay type are as presented Table [3](#Tab3){ref-type="table"} and Additional file [5](#MOESM5){ref-type="media"} and show considerable heterogeneity. Table 3Subgroup analyses by RT-PCR assay typeRT-PCR assay typeSummary measure of test accuracy^a^ (95% CI)Test for heterogeneity(*χ* ^2^) (df = 24)(*I* ^2^)*p* valueCobasTaqMan (*n* = 17; ^b^19,814) AUC = 0.98 Sensitivity0.78 (0.76--0.80)205.1392.20%\< 0.001 Specificity0.99 (0.99--0.99)127.2187.40%\< 0.001 Positive likelihood ratio (PLR)41.59 (27.80--62.18)98.1483.70%\< 0.001 Negative likelihood ratio (NLR)0.18 (0.13--0.23)134.3688.10%\< 0.001 Diagnostic odds ratio (DOR)273.14 (181.45--411.17)47.666.40%\< 0.001Light Cycler (*n* = 7; ^b^1159) AUC = 0.97 Sensitivity0.85 (0.80--0.88)61.7190.30%\< 0.001 Specificity0.99 (0.98--0.99)10.0940.50%0.121 Positive likelihood ratio (PLR)21.65 (6.82--68.72)17.4565.60%0.008 Negative likelihood ratio (NLR)0.17 (0.08--0.38)63.7790.60%\< 0.001 Diagnostic odds ratio (DOR)150.52 (31.97--708.78)20.3570.50%\< 0.002Cepheid and others (*n* = 22; ^b^14,839) AUC = 0.99 Sensitivity0.78 (0.77--0.80)729.4397.10%\< 0.001 Specificity0.99 (0.99--0.99)299.1393.00%\< 0.001 Positive likelihood ratio (PLR)38.50 (19.65--75.42)234.6291.00%\< 0.001 Negative likelihood ratio (NLR)0.22 (0.15--0.33)594.3096.50%\< 0.001 Diagnostic odds ratio (DOR)221.44 (94.94--516.51)208.2589.90%\< 0.001*χ* ^2^ chi-squared, *df* degree of freedom, *I* ^2^ I-squared, *n* number of studies, *CI* confidence interval, *AUC* area under receiver operating characteristics curve^a^Random-effects model^b^Number of specimens

Subgroup analyses by RT-PCR assay target sequence gene {#Sec15}
------------------------------------------------------

I.With IS6110 as the RT-PCR assay target sequence gene (22 studies, 12,004 specimens), the results were as follows: sensitivity 0.79 (0.77--0.81), specificity 0.98 (0.98--0.98) and AUC 0.99. A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper left corner, the higher the overall accuracy of the test. The summary estimates of IS6110 heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 470.30, 150.16, 134.64, 356.22 and 141.04, respectively, and *p* = 0 indicating significant heterogeneity across studies. *I* ^2^ was between 85.10 and 95.50% showing significant heterogeneity. The results for subgroup analysis by RT-PCR assay target sequence gene are presented in Table [4](#Tab4){ref-type="table"} and Additional file [5](#MOESM5){ref-type="media"} and show considerable heterogeneity.II.With 16S rRNA as the RT-PCR assay target sequence gene (7 studies, 12,074 specimens), the results were as follows: sensitivity 0.69 (0.66--0.71), specificity 0.99 (0.99--0.99) and AUC 0.97. A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper left corner, the higher the overall accuracy of the test (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 45.85, 32.10, 34.60, 19.87 and 9.12, respectively, and *p* \< 0.167 indicating significant heterogeneity across studies. *I* ^2^ was between 86.90 and 34.20% showing significant heterogeneity. The results for subgroup analysis by RT-PCR assay target sequence gene are presented in Table [4](#Tab4){ref-type="table"} and Additional file [5](#MOESM5){ref-type="media"} and show considerable heterogeneity.III.With other genes (see Table [1](#Tab1){ref-type="table"}) as the RT-PCR assay (17 studies, 11,870 specimens) the results were as follows: sensitivity 0.82 (0.80--0.84), specificity 0.99 (0.99--0.99) and AUC 0.98. A test with perfect discrimination has a ROC curve that passes through the upper left corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper left corner, the higher the overall accuracy of the test. The summary estimates of other genes heterogeneity with chi-squared (*χ* ^2^) using 95% CI for sensitivity, specificity, PLR, NLR and DOR were 413.02, 173.35, 123.92, 498.03 and 125.08, respectively, and *p* \< 0.001 indicating significant heterogeneity across studies. *I* ^2^ was between 87.20 and 96.10% showing significant heterogeneity. The results for subgroup analysis by RT-PCR assay target sequence gene are presented in Table [4](#Tab4){ref-type="table"} and Additional file [5](#MOESM5){ref-type="media"} and show considerable heterogeneity. Table 4Subgroup analyses by RT-PCR assay target sequence geneRT-PCR assay genesSummary measure of test accuracy^a^ (95% CI)Test for heterogeneity(*χ* ^2^) (df = 24)(*I* ^2^)*p* valueIS6110 (*n* = 22; ^b^12,004) AUC = 0.99 Sensitivity0.79 (0.77--0.81)470.3095.50%\< 0.001 Specificity0.98 (0.98--0.98)150.1686.00%\< 0.001 Positive likelihood ratio (PLR)31.76 (20.12--50.13)134.6484.40%\< 0.001 Negative likelihood ratio (NLR)0.17 (0.12--0.24)356.2294.10%\< 0.001 Diagnostic odds ratio (DOR)243.69 (127.07--437.37)141.0485.10%\< 0.00116S rRNA (*n* = 7; ^b^12,074) AUC = 0.97 Sensitivity0.69 (0.66--0.72)45.8586.90%\< 0.001 Specificity0.99 (0.99--0.99)32.1081.30%\< 0.001 Positive likelihood ratio (PLR)67.64 (36.40--125.70)34.6082.50%\< 0.001 Negative likelihood ratio (NLR)0.29 (0.24--0.36)19.8769.8%0.003 Diagnostic odds ratio (DOR)287.19 (193.85--425.46)9.1234.20%0.167Other genes (*n* = 17; ^b^11,870) AUC = 0.98 Sensitivity0.82 (0.80--0.84)413.0296.10%\< 0.001 Specificity0.99 (0.99--0.99)173.3590.80%\< 0.001 Positive likelihood ratio (PLR)42.48 (20.66--87.36)123.9287.10%\< 0.001 Negative likelihood ratio (NLR)0.22 (0.13--0.37)498.0396.80%\< 0.001 Diagnostic odds ratio (DOR)234.56 (86.01--639.63)125.0887.20%\< 0.001*χ* ^*2*^ chi-squared, *df* degree of freedom, *I* ^*2*^ I-squared, *n* number of studies, *CI* confidence interval, *AUC* area under receiver operating characteristics curve, *IS6110 Mycobacterium tuberculosis* complex-specific insertion sequence, *16S rRNA* 16S ribosomal RNA gene of MTB, *Other genes* rpoB as target sequence, mpt64 gene, 81-bp rpoB gene, senX3-regX3 intergenic region, 61 genomic DNA (gDNA) samples of MTB, cytochrome P450 Cyp 141 gene^a^Random-effects model^b^Number of specimen

Discussion {#Sec16}
==========

Tuberculosis is a global health threat and early and accurate diagnosis is crucial for preventing morbidity and mortality. Various methods are employed for the diagnosis of TB such as smear microscopy, culture identification, histopathology, tuberculin skin test (TST), serological assays, interferon-gamma release assays (IGRAs) and nucleic acid amplification (NAA) tests \[[@CR68], [@CR69]\]. Smear microscopy is widely used in the diagnosis of TB but has drawbacks owing to low and variable sensitivity values (0--40%) and cannot readily differentiate between MTB and non-tuberculous mycobacteria (NTM) \[[@CR70]--[@CR72]\]. Culture identification for MTB also has variable sensitivities (0--80%) in different TB specimens \[[@CR63], [@CR73]--[@CR75]\] with turn-a-round time of 2--10 weeks requiring the use of skilful technicians \[[@CR76]\]. Diagnosis of TB from tissue samples is usually made by histopathological examination that depends on the presence of granulomatous inflammation and caseous necrosis \[[@CR70], [@CR77]\]. However, histology does not distinguish between EPTB and infections from other granulomatous diseases such as NTM, sarcoidosis, leprosy and systemic lupus erythematosus (except for the presence of acid-fast bacilli (AFB)) \[[@CR78], [@CR79]\]. RT-PCR is a novel and robust assay primarily used to quantify the nucleic acids in all TB specimens \[[@CR63], [@CR80]--[@CR82]\]. The main advantages of RT-PCR are shortened turn-a-round time, quantification of bacterial load and automation of the procedure that reduces hands-on time and decreased risk of cross-contamination \[[@CR63], [@CR83]\]. This review provides evidence on the effectiveness of RT-PCR assay for the rapid and accurate detection of MTB from pathological samples. To our knowledge, this is the first systematic review and meta-analysis for ascertaining the effectiveness of RT-PCR assays for the detection of MTB from both pulmonary and extra-pulmonary pathological samples.

In this study, results indicated that RT-PCR assay produces consistent results with high specificity of 0.99 (95% CI 0.99--0.99), PLR of 43.0 (28.23--64.81) and NLR of 0.16 (0.12--0.20) for PTB, whereas specificity, PLR and NLR were 0.99 (95% CI, 0.99--0.99), 29.82 (17.86--49.78) and 0.33 (0.26--0.42), respectively, for EPTB. A PLR of 43 suggests that patients with a pulmonary MTB infection have a 43-fold higher chance of being RT-PCR test positive compared with patients without the infection. This ratio suggests a potential role for RT-PCR assay in confirming (ruling in) a MTB infection.

The summary estimates of sensitivity, however, were 0.82 (95% CI 0.81--0.83) and 0.70 (95% CI 0.67--0.72) for pulmonary and extra-pulmonary samples, respectively, higher in pulmonary than extra-pulmonary TB possibly due to paucity of tubercle bacilli in extra-pulmonary samples. Sensitivity estimates were more variable than specificity. According to the AUC and the DOR (see Table [2](#Tab2){ref-type="table"}), diagnostic accuracy of RT-PCR assay was excellent for the pulmonary specimens over extra-pulmonary and these results are acceptable for clinical practice (see Table [2](#Tab2){ref-type="table"}).

A RT-PCR assay for the detection of MTB has a high sensitivity and specificity. The PLR and NLR showed that RT-PCR may serve as a suitable method when confirming or excluding TB. It was anticipated that there would be some degree of heterogeneity of diagnostic measures across studies due to differences in sample size, RT-PCR assay type, reference test (either liquid or solid or both) and TB prevalence. High heterogeneity was found among studies (as defined by the *χ* ^2^ and *I* ^2^ statistics) for all measures. Subgroup analyses were therefore performed pre-specified to investigate potential sources of the observed between-study heterogeneity. It was assumed that the disparity was likely a result of the differences in the type of index test (RT-PCR assay) or target sequence gene of MTB used.

In the current study, a limited number of subgroup analyses were conducted by comparing CobasTaqMan, Light Cycler, Cepheid and others as RT-PCR assay types to reduce the degree of study heterogeneity. Heterogeneity assessed by *χ* ^2^ and *I* ^2^ statistics between these subgroups was generally not very strong (see Table [3](#Tab3){ref-type="table"}). However, significant heterogeneity of diagnostic accuracy measures was expected and was, indeed, found among studies and the random-effects model partially accounted for the between-study heterogeneity.

Some degree of heterogeneity of diagnostic measures across studies was found due to differences in sample size, study design, target genes and clinical settings of the participants. Thus, it is possible that when evaluating RT-PCR assays using a more sensitive index test can lead to overestimation of the assay's sensitivity. No significant differences in specificities of the different types of index tests were observed.

Strengths and weaknesses of the review {#Sec17}
--------------------------------------

An important strength of this study was its comprehensive search strategy using several search engines to identify any unpublished studies in the form of conference abstracts or proceedings. Screening, study selection, quality assessment and data extraction were undertaken independently and reproducibly by two reviewers, as such human error should be limited. The problem of missing data was reduced by contacting the authors of the publications. In accordance with the study guidelines, potential publication bias and heterogeneity was explored \[[@CR15], [@CR84]\]. Evaluation of level of publication bias was not formally carried out in the study; however, the risk of this bias was reduced by not restricting the search to any language. In addition, we contacted experts for information on additional studies. Another strength of this review is that RT-PCR assay has comparably high sensitivity with paucibacillary specimens and high throughput capacities.

This review does, however, have some limitations in assessing issues such as cost-effectiveness and the net effect of RT-PCR assay on clinical care and patient outcomes. Also, because of poor reporting, an analysis of the effect of factors such as laboratory infrastructure was not possible. Secondly, empirical evidence suggests that studies with significant or favourable results are more likely to be published than those with non-significant or unfavourable results \[[@CR85]\]. In addition, literature search strategies are inherently imperfect and studies can be missed, it is therefore possible that a proportion of such studies with non-significant or unfavourable results may have been missed. Other limitations are conflicts of interest of study authors particularly from industry supported studies and fully keeping up to date with the primary studies in this rapidly evolving field.

Given that RT-PCR assays in this review cover a wide range of different target genes and procedures, it is not possible to recommend any one over another owing to a lack of direct test comparisons. Our findings should be interpreted in the context of the quality of studies and reporting and variability in study quality. Diagnostic studies in general \[[@CR86]\] and TB diagnostic studies in particular \[[@CR87]\] seem to be beset by these problems.

Implications for research and clinical practice {#Sec18}
-----------------------------------------------

Current evidence suggests a potential role for RT-PCR assay in confirming a diagnosis of TB. It offers an alternative robust approach to detect MTB in paucibacillary EPTB samples that provides rapid results with good diagnostic accuracy. The results of this assay type should be interpreted in parallel with clinical findings and the results of conventional tests; but the assay contributes significantly for an early diagnosis and exerts an impact on clinical management and control of TB. Our findings do not support the use of this assay type for excluding diagnosis of tuberculosis as standalone test.

For EPTB, clinical judgement has both poor sensitivity and specificity. The NICE guidelines recommend the use of culture, histology and/or chest X-ray for patients with non-respiratory TB \[[@CR88]\]. Consequently, outcomes of a negative smear for acid-fast bacilli, lack of granulomas on histopathology and failure to culture MTB do not exclude the diagnosis of EPTB; RT-PCR assay has proved to be a novel diagnostic modality in varied forms of EPTB. This review suggests RT-PCR assay can be of help as a most specific test in a 'rule-in decision' for MTB detection.

The reliability of RT-PCR to confirm an early diagnosis of TB meningitis and abdominal TB has been well established when smear and culture tests are rarely positive \[[@CR89], [@CR90]\]. It has also proved useful for an early diagnosis of osteoarticular TB in tissue samples and that can help to start timely, appropriate anti-tubercular therapy (ATT) \[[@CR91]\] and prevent progression to irreversible tissue changes. Due to small sample volumes available, irregular dispersion of MTB in specimens both viable and non-viable, RT-PCR has aided in detecting MTB compared with conventional tests from an array of different cases of EPTB such as pericardial tuberculosis, disseminated/miliary tuberculosis, thyroid tuberculosis, ocular tuberculosis, tuberculous mastitis and others \[[@CR90]\].

Future studies should compare commercialised RT-PCR assays to determine their diagnostic accuracy. The use of guidelines such as the Standards for Reporting of Diagnostic Accuracy (STARD) might improve the quality of reporting of primary studies \[92\]. Further work is required to devise a simple and cost-effective RT-PCR test for an efficient diagnosis of TB that can be used routinely in resource-poor countries.

Conclusion {#Sec19}
==========

According to this review and meta-analysis, RT-PCR assay has a high sensitivity and specificity for PTB with turn-a-round time of 2 h compared with reference culture-based assay that takes between 2 and 10 weeks for detection. Overall, RT-PCR assay accuracy was superior for pulmonary samples (sensitivity 0.82 (95% CI 0.81--0.83); specificity 0.99 (95% CI 0.99--0.99)) as opposed to extra-pulmonary samples (sensitivity 0.70 (95% CI 0.67--0.72); specificity 0.99 (95% CI 0.99--0.99)) possibly due to paucibacillary. The specificity was high for both pulmonary and extra-pulmonary samples indicating that the test should be adopted as the first-line test for ruling in TB infection but may need to be an add-on test to rule out the disease. It offers an alternative robust approach to detect MTB in paucibacillary EPTB samples, showing rapid results with good diagnostic accuracy. The results of this assay should be interpreted in parallel with clinical findings and the results of conventional tests, but the assay may contribute significantly for an early diagnosis and exert an impact on the clinical management and control of TB. The findings do not support the use of this assay for excluding a diagnosis of TB on its own as a standalone test. It offers an incremental benefit as an add-on test to other investigations. RT-PCR assays, combining amplification and detection in a single run, seem to offer advantages over conventional assays including the reference standard.

From the data of investigations of heterogeneity, factors such as RT-PCR assay types (CobasTaqMan, Light Cycler, Cepheid and others) and RT-PCR assay target sequence genes (IS6110, 16SRNA and other genes) were considered to have influenced the accuracy estimates.

It is anticipated that our findings will aid healthcare practitioners and policymakers in adopting the use of this assay on a routine basis. Most importantly, this can be as a point-of-care-test which will help in the global control of MTB, particularly in developing countries with a high burden of the disease.
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